Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.60 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.45 |
| ▸ | TDO2 | P48775 | 9/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16703358 | 0.81 | GRM4 (0.65) | GRM4IMPDH2MAPK1HSD17B10SIRT2 | |
| SCHEMBL18045685 | 0.77 | GRM4 (0.60) | GRM4IMPDH2MAPK1HSD17B10SIRT2 | |
| SCHEMBL18045679 | 0.75 | GRM4 (1.00) | GRM4IMPDH2MAPK1HSD17B10NR4A2 | |
| SCHEMBL18045673 | 0.74 | GRM4 (0.80) | GRM4IMPDH2MAPK1HSD17B10SIRT2 | |
| SCHEMBL18045684 | 0.71 | GRM4 (0.80) | GRM4IMPDH2MAPK1HSD17B10NR4A2 | |
| SCHEMBL18045678 | 0.71 | GRM4 (0.80) | GRM4IMPDH2MAPK1HSD17B10NR4A2 | |
| SCHEMBL16703485 | 0.71 | GRM4 (0.80) | GRM4IMPDH2MAPK1HSD17B10NR4A2 | |
| SCHEMBL18045677 | 0.71 | GRM4 (0.74) | GRM4MAPK1PDGFRBPDGFRAKDR | |
| SCHEMBL28377762 | 0.70 | NR4A2 (0.81) | GRM4IMPDH2MAPK1HSD17B10SIRT2 | |
| 3-Phenylindole SCHEMBL84056 | 0.69 | IMPDH2 (0.71) | GRM4IMPDH2MAPK1HSD17B10SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263087-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2016-09-15 | — | — | US | claimed |
| US-20160263087-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263087-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, TPH1 | GRM4 1668/4885IMPDH2 1348/4885MAPK1 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.